Metformin and Type 2 Diabetes Prevention
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
IN BRIEF Metformin, an established therapy for the treatment of type 2 diabetes, has demonstrated safety and effectiveness in the prevention or delay of type 2 diabetes in people at high risk. The Diabetes Prevention Program randomized clinical trial demonstrated that intensive lifestyle intervention and metformin therapy reduced progression to diabetes by 58 and 31%, respectively, compared to placebo in people at risk of type 2 diabetes. Although lifestyle intervention was beneficial in all groups, metformin had a selectively greater effect in those who were more obese, had a higher fasting glucose, had a history of gestational diabetes, or were younger. Long-term effects included an 18% diabetes reduction with metformin compared to placebo over 15 years, a reduction in microvascular complications among those who did not progress to diabetes (without difference among treatment arms), and suggestion by coronary calcium assessment of a possible impact on atherosclerosis in men. Although long-term follow-up to assess later-stage outcomes is underway, current efforts to address gaps in evidence and translation remain of significant public health interest.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“metformin was no more effective than the control condition in older adults.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“Notably, those older than 60 years showed the best response, with a 71% reduction in incident diabetes during this timeframe.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“By contrast, metformin was no more effective than the control condition in older adults.”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“In the DPP, participants randomly assigned to an intensive lifestyle intervention including diet and exercise reduced their risk of incident T2D by 58% at three years compared to the control group (lifestyle advice only), and this intervention was significantly better than metformin prescription [386].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
In the citing paper
“In the DPP, participants randomly assigned to an intensive lifestyle intervention including diet and exercise reduced their risk of incident T2D by 58% at three years compared to the control group (lifestyle advice only), and this intervention was significantly better than metformin prescription [386].”
From Global consensus on optimal exercise recommendations for enhancing healthy longevity in older adults (ICFSR) (2025) · cites this paper as [386]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Diabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020
Ramachandran, A., Snehalatha, C., Mary, S., Mukesh, B., Bhaskar, A. D., Vijay, V., & Indian Diabetes Prevention Programme (IDPP) (2006) · Diabetologia · doi:10.1007/s00125-005-0097-z · Cited by 1,881
Metformin: historical overview
Bailey, C. J. (2017) · Diabetologia · doi:10.1007/s00125-017-4318-z · Cited by 1,055 · cited 2×
“Metformin, a guanidine derivative, was ultimately introduced as an agent to treat diabetes in the 1950s in Europe and in the 1990s in the United States (1).”
Background(2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00291-0 · Cited by 1,029
Orchard, T. J., Temprosa, M., Goldberg, R., Haffner, S., Ratner, R., Marcovina, S., Fowler, S., & for the Diabetes Prevention Program Research Group (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-8-200504190-00009 · Cited by 948 · cited 1×
“Although no significant differences in blood pressure or lipids were seen compared to placebo during the DPP (15), metformin improved lipoprotein subfractions (16), C-reactive protein (CRP) (17), and tissue plasminogen activator (tPA) (17) and reduced the incidence of metabolic syndrome by 17% (18).”
BackgroundSelf-citationRatner, R. E., Christophi, C. A., Metzger, B. E., Dabelea, D., Bennett, P. H., Pi-Sunyer, X., Fowler, S., Kahn, S. E., & The Diabetes Prevention Program Research Group (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0772 · Cited by 867 · cited 1×
“Namely, metformin was comparable to intensive lifestyle intervention in obese individuals with a BMI ≥35 kg/m2, demonstrating a 53% reduction in progression to diabetes (compared to 51% for lifestyle); in younger individuals aged 25–44 years, with a 44% reduction compared to 48% with lifestyle (3); and in women with a…”
BackgroundSelf-citation(1999) · Diabetes Care · doi:10.2337/diacare.22.4.623 · Cited by 725
The Diabetes Prevention Program Research Group (2005) · Diabetes Care · doi:10.2337/diacare.28.4.888 · Cited by 572 · cited 1×
“Although no significant differences in blood pressure or lipids were seen compared to placebo during the DPP (15), metformin improved lipoprotein subfractions (16), C-reactive protein (CRP) (17), and tissue plasminogen activator (tPA) (17) and reduced the incidence of metabolic syndrome by 17% (18).”
Background
Cited by
International exercise recommendations in older adults (ICFSR): Expert consensus guidelines
Izquierdo, M., Merchant, R. A., Morley, J. E., Anker, S. D., Aprahamian, I., Arai, H., Aubertin-Leheudre, M., Bernabei, R., Cadore, E. L., Cesari, M., et al. (2021) · The Journal of nutrition, health and aging · doi:10.1007/s12603-021-1665-8 · Cited by 1,247
Tirzepatide for Obesity Treatment and Diabetes Prevention
Jastreboff, A. M., le Roux, C. W., Stefanski, A., Aronne, L. J., Halpern, B., Wharton, S., Wilding, J. P. H., Perreault, L., Zhang, S., Battula, R., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2410819 · Cited by 462
Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
Dutta, S., Shah, R. B., Singhal, S., Dutta, S. B., Bansal, S., Sinha, S., & Haque, M. (2023) · Drug Design, Development and Therapy · doi:10.2147/dddt.s409373 · Cited by 248
“In prediabetes, it was also used to delay or prevent diabetes onset.(183)”
MethodIzquierdo, M., de Souto Barreto, P., Arai, H., Bischoff-Ferrari, H. A., Cadore, E. L., Cesari, M., Chen, L.-K., Coen, P. M., Courneya, K. S., Duque, G., et al. (2025) · The Journal of nutrition, health and aging · doi:10.1016/j.jnha.2024.100401 · Cited by 273
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 171
Diabetes and cardiovascular disease: inter-relation of risk factors and treatment
Sharma, A., Mittal, S., Aggarwal, R., & Chauhan, M. K. (2020) · Future Journal of Pharmaceutical Sciences · doi:10.1186/s43094-020-00151-w · Cited by 99
Mokgalaboni, K., Lebelo, S. L., Modjadji, P., & Ghaffary, S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1132650 · Cited by 54
“Although readily available medicines such as metformin have proven to be beneficial in treating T2D and metabolic conditions by controlling glucose levels (Aroda and Ratner, 2018; Dludla et al., 2021), there is still a continuous rise in the death rate associated with T2D complications.”
BackgroundGestational Diabetes: An Update 60 Years After O’Sullivan and Mahan
McIntyre, H. D., Kampmann, U., Dalsgaard Clausen, T., Laurie, J., & Ma, R. C. W. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae709 · Cited by 32
The circadian rhythm: an influential soundtrack in the diabetes story
Hariri, A., Mirian, M., Zarrabi, A., Kohandel, M., Amini-Pozveh, M., Aref, A. R., Tabatabaee, A., Prabhakar, P. K., & Sivakumar, P. M. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1156757 · Cited by 30
The Interplay of Uterine Health and Obesity: A Comprehensive Review
Šišljagić, D., Blažetić, S., Heffer, M., Vranješ, M., & Müller, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122801 · Cited by 33
From Diabetes to Atherosclerosis: Potential of Metformin for Management of Cardiovascular Disease
Poznyak, A. V., Litvinova, L. S., Poggio, P., Moschetta, D., Sukhorukov, V. N., & Orekhov, A. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179738 · Cited by 30
“Ultimately, these two methods of intervention may hinder atherosclerosis development and progression [73].”
Yan, N., Wang, L., Li, Y., Wang, T., Yang, L., Yan, R., Wang, H., & Jia, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0254321 · Cited by 30
“ApoE mice characterized by severe hypercholesterolemia due to a virtually completely blocked LDL-receptor mediated lipoprotein remnant clearance, fed with HFD, have been widely reported as a classical AS model [36, 37].”
BackgroundMicroRNAs Associated with Metformin Treatment in the Diabetes Prevention Program
Lewis, K., STROEBEL, B. M., Zhang, L., Aouizerat, B. E., Mattis, A. N., & Flowers, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115684 · Cited by 23
Khanal, P., Dwivedi, P. S. R., Patil, V. S., Shetty, A., Adithya, S., Aga, A., Akshith, R., Javaid, A., & Bhandare, V. V. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2233631 · Cited by 23
“Metformin also reduces postprandial glucose levels by up to 30% and has been proven to improve insulin sensitivity and reduce the risk of long-term complications such as cardiovascular disease and neuropathy (Aroda & Ratner, 2018).”
BackgroundBanerjee, R., Zhu, Y. G., Brownrigg, G. P., Moravcova, R., Rogalski, J. C., Foster, L. J., Johnson, J. D., & Kolic, J. (2024) · Endocrinology · doi:10.1210/endocr/bqae079 · Cited by 20
“Studies highlighting the benefits of the ketogenic diet have even led to an increase in the popularity of exogenous ketone supplements in an effort to further promote weight loss and slow the onset of type 2 diabetes (T2D) in prediabetic patients (15).”
BackgroundCurrent Perspectives for Treating Adolescents with Obesity and Type 2 Diabetes: A Review
Niechciał, E., Wais, P., Bajtek, J., & Kędzia, A. W. (2024) · Nutrients · doi:10.3390/nu16234084 · Cited by 26
Gedawy, A., Al‐Salami, H., & Dass, C. R. (2020) · Therapeutic Delivery · doi:10.4155/tde-2020-0102 · Cited by 19
Thipsawat, S. (2023) · SAGE Open Nursing · doi:10.1177/23779608231175581 · Cited by 22
“Metformin therapy should be recommended for the prevention of T2DM in individuals with prediabetes (Aroda & Ratner, 2018), particularly those aged 60 years and those with a BMI≥ 35 kg/m2.”
BackgroundTargeting Aging with Metformin (TAME)
Padki, M. M., & Stambler, I. (2021) · Springer eBooks · doi:10.1007/978-3-030-22009-9_400 · Cited by 18
Mayadunne, T., Saadati, S., Asmelash, D., Mason, T., Vanky, E., Teede, H. J., & Mousa, A. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16418 · Cited by 17
“7,8 Metformin is also recommended by International Evidence-based Guidelines for the general management of metabolic symptoms in polycystic ovary syndrome (PCOS), a highly prevalent endocrine disorder that affects approximately 10 – 13% of women of reproductive age.”
Hong, J., Pham, T. X., Lee, J., Raslan, A., Nicolas, K., Sharov, A. A., Meridew, J. A., Urrutia, R. A., Lomberk, G. A., Huang, S. K., et al. (2024) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2024-0255oc · Cited by 14
Metformin reduces the risk of developing influenza A virus related cardiovascular disease
Lee, H. S., Noh, J. Y., Song, J. Y., Cheong, H. J., & Kim, W. J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20284 · Cited by 14
Two sides of the same coin: Non-alcoholic fatty liver disease and atherosclerosis
Zhu, B., Wu, H., Li, K. S., Eisa-Beygi, S., Singh, B., Bielenberg, D. R., Huang, W., & Chen, H. (2023) · Vascular Pharmacology · doi:10.1016/j.vph.2023.107249 · Cited by 15
Uddin, S., Machado, M. S., Alshahrouri, B., Echeverri, J. I., Rico, M. C., Rao, A. D., Ruchalski, C., & Barrero, C. A. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14113822 · Cited by 15
“Adverse effects associated with metformin therapy typically relate to gastrointestinal intolerance, rare cases of lactic acidosis in patients with a glomerular filtration rate (GFR) below 30 mL/min/1.73 m 2 , and B12 deficiency that can worsen neuropathic symptoms [64,65].”
InfluentialUboldi, M., Chiappa, A., Rossi, M., Vangosa, F. B., Melocchi, A., & Zema, L. (2023) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2023.2294884 · Cited by 15
“As a consequence, patients are currently forced to assume the drug several times through the day (generally 500–1000 mg taken twice a day), which often leads to nausea, diarrhea, loss of appetite and lactic acidosis due to the burst effect resulting from each administration [61– 64].”
BackgroundWasner, H. K. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042200 · Cited by 12
“A more recent observation is that metformin helps diabetics for a longer time [31].”
BackgroundPencina, K. M., Thanassoulis, G., Pencina, M. J., Toth, P. P., & Sniderman, A. D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02525-3 · Cited by 10
Efficacy of metformin and electrical pulses in breast cancer MDA-MB-231 cells
Sahu, P., Camarillo, I. G., & Sundararajan, R. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00204 · Cited by 10
Oo, T. T., Sumneang, N., Ongnok, B., Arunsak, B., Chunchai, T., Kerdphoo, S., Apaijai, N., Pratchayasakul, W., Liang, G., Chattipakorn, N., et al. (2021) · British Journal of Pharmacology · doi:10.1111/bph.15741 · Cited by 10
“To date, metformin is the first drug of choice for patients with prediabetes (Aroda & Ratner, 2018).”
BackgroundRetractedAlfayez, O. M., Alsallum, A., Aljabri, A. F., Almutairi, F. S., AlAzzeh, O., Almalki, O. S., Yami, M. S. A., & Almohammed, O. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.989072 · Cited by 10
“Although metformin is considered a very safe medication, it has some side effects, such as gastrointestinal disorders and B12 deficiency, that may hinder the prescribing or use of this medication as a protective measure (22).”
BackgroundInfluentialMokgalaboni, K., Phoswa, W. N., Mokgalabone, T. T., Dlamini, S. T., Ndhlala, A. R., Modjadji, P., & Lebelo, S. L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252010922 · Cited by 9
“Although the antidiabetic drugs and supplements used in T2D can potentially ameliorate hyperglycemia, we acknowledge their limitations in T2D [19,20].”
BackgroundMetformin alleviates lung-endothelial hyperpermeability by regulating cofilin-1/PP2AC pathway
Siddiqui, M. R., Reddy, N. M., Faridi, H. M., Shahid, M., & Shanley, T. P. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1211460 · Cited by 9
“Metformin, a biguanide, is an effective glucose lowering drug widely prescribed for the management of type 2 diabetes (Aroda and Ratner, 2018).”
BackgroundToxicology of pharmaceutical and nutritional longevity compounds
Kahraman, Ç., Bilecenoglu, D. K., Sabuncuoğlu, S., & Çankaya, İ. İ. T. (2023) · Expert Reviews in Molecular Medicine · doi:10.1017/erm.2023.18 · Cited by 8
Atrial fibrillation and prediabetes: A liaison that merits attention!
Batta, A., & Hatwal, J. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i7.1645 · Cited by 7
Astrocytes at the intersection of ageing, obesity, and neurodegeneration
Firth, W., Pye, K. R., & Potter, P. G. W. (2024) · Clinical Science · doi:10.1042/cs20230148 · Cited by 6
“For example, promoting insulin signalling via the sensitiser metformin is a first-line treatment for T2DM 263–265 , a disorder characterised by loss of insulin sensitivity 266 .”
Ibrahim, M. J., Nangia, A., Das, S., Verma, T., Rajeswari, V. D., Venkatraman, G., & Ramanathan, G. (2024) · Cell Biochemistry and Biophysics · doi:10.1007/s12013-024-01511-6 · Cited by 6
“While Metformin, a fi rst-line medication for T2DM, effectively manages blood glucose levels, its utilization is hindered by gastrointestinal disturbances and tolerance issues [1, 2].”
Jankevičiūtė, S., Svirskienė, N., Svirskis, G., & Borutaitė, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22179493 · Cited by 7
Reynés, B., Palou, M., Palou, A., & Serra, F. A. (2022) · Journal of Functional Foods · doi:10.1016/j.jff.2022.105223 · Cited by 5
Krysiak, R. G., Kowalcze, K. E., Szkróbka, W., & Okopień, B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081093 · Cited by 4
“…explain why the gland accumulates much higher quantities of metformin, the most commonly used antidiabetic agent in the world and the only American-Diabetes-Association-recommended drug for prediabetes [2,3], compared with the central nervous system, both after acute and chronic administration [4].”
BackgroundLi, J., Jiang, Q., Wang, X., Hou, L., Wang, L., Lou, K., & Pang, S. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073246747230920170201 · Cited by 6
Survey of Primary Care Physicians’ Knowledge, Practices & Perceptions of Prediabetes in Bahrain
Tadayyon, B. E., Qader, M., & AlDoseri, S. F. (2022) · Journal of the Bahrain Medical Society · doi:10.26715/jbms.34_3_3 · Cited by 4
Kumar, M., Prabhakar, P., Hameed, S., Kumar, M., Shekhar, R., Kumar, B., & Dikshit, H. (2025) · International Journal of Applied and Basic Medical Research · doi:10.4103/ijabmr.ijabmr_580_24 · Cited by 3
Saber, N. S. A., & AL-mihanya, R. H. (2025) · AL-Kindy College Medical Journal · doi:10.47723/qv85p752 · Cited by 4
Repurposing the hypoglycaemic agents for neuroinflammation, a comprehensive review
Blossom, V., Ullal, S. D., Rai, R., souza, M. M. D., Kalluraya, P. G. G., Dixit, A., Jiji, P. J., & Murlimanju, B. V. (2025) · 3 Biotech · doi:10.1007/s13205-025-04455-7 · Cited by 3
“By targeting the glutamatergic and inflammatory pathways, pioglitazone can help reduce Aβ levels, which are associated with neuroinflammation and cognitive impairment (Aroda and Ratner 2018).”
Global implications of diabetes biomedicalization
Brantly, N. D. (2025) · Social Theory & Health · doi:10.1057/s41285-025-00240-x · Cited by 3
“Interestingly, increased use of diabetes drugs like Metformin (Ding and Glied 2022), despite showing positive outcomes in halting the progression of prediabetes to diabetes (Aroda and Ratner 2018), has not resulted in a population-level decrease in the prevalence of T2D (CDC 2024).”
Yuvaraaj, V. K., Azhlwar, S., & KRISHNAMOORTHY, V. (2025) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2025.82654 · Cited by 3
Dietary Consumption on Glycemic Control Among Prediabetes: A Review of the Literature
Thipsawat, S. (2023) · SAGE Open Nursing · doi:10.1177/23779608231218189 · Cited by 4
“(Aroda & Ratner, 2018).”
Shaheer, A., Kumar, A., Menon, P. B., Jallo, M. K. I., & Basha, S. A. (2021) · Journal of Endocrinology and Metabolism · doi:10.14740/jem751 · Cited by 3
“Metformin reduces hepatic glucose production, inhibits the intestinal absorption of glucose, and improves insulin sensitivity by promoting glucose uptake and utilization [18-20].”
Hypoglycemic activity of ethanol leaf extract of Grona trifloral in alloxan induced diabetic mice
Mbagwu, I. S., Oraekei, D. I., & Onah, L. C. (2023) · GSC Biological and Pharmaceutical Sciences · doi:10.30574/gscbps.2023.24.3.0347 · Cited by 4
Evaluating the metformin use on type 2 diabetes prevention in high-risk populations in primary care
Álvarez‐Villalobos, N. A., Ramírez-Torres, A. I., Ruiz-Hernández, F. G., Elizondo-Omaña, G. G., García-Hernández, R. M., Peña, P. J. M., & Rojo-Garza, S. S. (2024) · Journal of Family Medicine and Primary Care · doi:10.4103/jfmpc.jfmpc_552_24 · Cited by 2
Impact of Metformin on BRCA1 Expression and Breast Cancer Risk in T2DM Patients
Hassan, H. H., & ullah, P. H. S. (2025) · Baghdad Science Journal · doi:10.21123/2411-7986.5050 · Cited by 2
Mahboub, B. M., Refaie, A. F., El-Haggar, S. M., Hafez, Y. M., & Mostafa, T. M. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-02040-9 · Cited by 2
“This antidiabetic effect may be related to its beneficial effect on preserving prediabetes from diabetes [66–68].”
Izadi, A., Zarourati, A., Boozarpour, S., Ghalandar, M., Lashkarboloki, M., Momeni‐Moghaddam, M., & Fahimi, M. (2025) · Reports of Biochemistry and Molecular Biology · doi:10.61882/rbmb.14.1.85 · Cited by 2
Banu, H., Al-Shammari, E., Bardakçi, F., Patel, M., Adnan, M., Khan, M. I., AlFahhad, N., & Ashraf, S. A. (2026) · Life · doi:10.3390/life16030530 · Cited by 2
“Several synthetic anti-diabetic drugs, such as metformin, sulfonylureas, and thiazo-lidinediones, are available on the market; however, the growing number of diabetic patients https://doi.org/10.3390/life16030530 and the emergence of secondary complications call for more effective therapies [19,20].”
InfluentialEvaluation of the invitro antidiabetic and anti-cholesterols activity of selected plant extract
Agustini, S. R., Asmaliyah, A., Hadi, E. E. W., & Imanullah, A. (2024) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/1356/1/012010 · Cited by 2
“It has the capacity to reduce the generation of glucose in the liver, postpone or prevent the absorption of glucose from the gastrointestinal tract, and is a medicine used to treat type 2 diabetes and gestational diabetes [19].”
Current opportunities for the prevention and treatment of carbohydrate metabolism disorders
Zilov, A. V., & Болиева, Л. З. (2024) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2024-540 · Cited by 2
The Returns to Preventing Chronic Disease in Europe and the United States
Yu, J. C., Tysinger, B., Mortari, A. P., Belotti, F., Ryan, M. S., Atella, V., & Goldman, D. P. (2022) · Journal of Human Capital · doi:10.1086/718513 · Cited by 2
Manjula, S., & Krishna Kumar, M. (2024) · International Journal of Advanced Research in Medicine · doi:10.22271/27069567.2024.v6.i2a.550 · Cited by 1
“Metformin, a well-established biguanide, regulates blood glucose by inhibiting ~ 32 ~ liver sugar production and absorption [6, 7] .”
Imkongyanger, I., Richa, K., Lotha, T. N., Ao, K., Rudithongru, L., Nakro, V., Ritse, V., Namsa, N. D., Pankaj, P. P., Sinha, U. B., et al. (2024) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303287962240621053459 · Cited by 1
Mohammed, N., Khan, S. A., Anne, B., Begum, T., Bhaskar, M. V., Sreedevi, N. N., & Saibaba, K. S. S. (2025) · Indian Journal of Medical Biochemistry · doi:10.5005/jp-journals-10054-0267 · Cited by 1
Svirskienė, N., Svirskis, G., Jankevičiūtė, S., & Borutaitė, V. (2025) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2025.110494 · Cited by 1
Farley, B., Radetich, E., D’Alessandro, J. S., & Bulaj, G. W. (2025) · Healthcare · doi:10.3390/healthcare13243220 · Cited by 2
“A different meta-analysis also found that while lifestyle modification decreased the incidence of T2DM by 58% compared to the control group, metformin decreased the incidence by 31% compared to the placebo group in most individuals [54].”
Real‐world predictors of progression to type 2 diabetes among adults with prediabetes
Dunn, T. J., Doshi, R., Divino, V. M., Chen, J., Radin, M. S., Tian, D., Xie, L., & Solis‐Herrera, C. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70583 · Cited by 2
“46 GLP-1 RAs, such as semaglutide and tirzepatide, also reduce progression from prediabetes to T2D, 47 and among patients with T2D, GLP-1 RAs effectively lower HbA1c and FPG levels.”
Gottwald‐Hostalek, U., & Mustafina, S. V. (2020) · Diabetes & its Complications · doi:10.33425/2639-9326.1070 · Cited by 1
“As the diagnosis of type 2 diabetes is made according to the level of plasma glucose, a reduction in plasma glucose with metformin may explain part of the reduction in the risk of diabetes observed in the DPP, and other randomised, controlled trials [14,16,21].”
Targeting Aging with Metformin (TAME)
Padki, M. M., & Stambler, I. (2019) · Springer eBooks · doi:10.1007/978-3-319-69892-2_400-1 · Cited by 1
The evidence behind early aggressive multi-drug treatment in type 2 diabetes
Cersósimo, E., Solis‐Herrera, C., & Triplitt, C. L. (2021) · Trends in Diabetes and Metabolism · doi:10.15761/tdm.1000121 · Cited by 1
Akhtar, F., Hamid, S., Abbas, A., Ehsan, S., Salam, R. A., & Anwer, K. (2022) · Pakistan Journal of Medical and Health Sciences · doi:10.53350/pjmhs20221612487
Kalra, S., Dhingra, A., Mahesh, D. M., Baruah, M. P., Tiwaskar, M., Agrawal, N., Deka, N., Kalra, P., Kale, S., & Revankar, S. (2024) · Liaquat National Journal of Primary Care · doi:10.37184/lnjpc.2707-3521.7.27
Metformin-Associated Lactic Acidosis Successfully Treated with Hemodialysis: A Case Report
Dweekat, M., Abugaber, D., Shakhshir, A., & Hamshary, Y. E. (2024) · Palestinian medical and pharmaceutical journal/Palestinian medical & pharmaceutical journal · doi:10.59049/2790-0231.1150
Influence of Ethyl Acetate Fraction of Cananga Odorata on Diabetic Model of Drosophila MelanogasterPreprint
Sanni, J. A., Saliu, J. A., Apata, S. A., Olubode, S. O., Adenuga, O.-O. O., Adenuga, V. O., & Atibor, R. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.5036678 · Cited by 1
AMPK Activation by 2′‐Hydroxy‐2,4,5‐Trimethoxychalcone Derivatives in Podocyte Cells
Nguyen, V., Muanprasat, C., Kaewin, S., Poolsri, W., & Chavasiri, W. (2025) · ChemMedChem · doi:10.1002/cmdc.202500177
Kulshrestha, A. K., Zala, U., Upadhye, V. J., & Shrivastav, A. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-30086-8.00003-6
Phenotypic spectrum of polycystic ovary syndrome in a tertiary care rural hospital in Eastern India
Darrshini, N. T. S., Mondal, J., Bala, S., Barua, M., Kyal, A., & Saha, M. K. (2026) · International Journal of Reproduction Contraception Obstetrics and Gynecology · doi:10.18203/2320-1770.ijrcog20260175
Type 2 Diabetes in the World and in Lithuania
Svirplytė-Burakauskienė, G. (2023) · Lithuanian University of Health Sciences
NEW ERA IN DIABETES AND OBESITY TREATMENT - THE EFFECTS OF GLP-1R, GIPR AND GCGR TRIAGONISTS
Duliński, M., Gofron, K. K., Kaźmierkiewicz, K., Spychalska, W., Piotrowicz, E., Witowicz, F., Glińska, J., Krawczyk, A., Waldon, W., & Sumlet, P. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.3(51).2026.6156
Hartany, L. O. A., Alghorab, M. A., Alhomieed, M. F., Albalawi, R. S., Almowallad, A. A., Alsharif, A., Amin, A. S., Alamri, S. F., Aljabal, T. K., & Alkthiry, A. (2026) · Diabetology · doi:10.3390/diabetology7080156
“Metformin primarily improves insulin sensitivity and reduces hepatic glucose production, thereby lowering circulating glucose concentrations and reducing metabolic stress on pancreatic β -cells [15].”
Metadata
- Authors
- Aroda, V. R., & Ratner, R. E.
- Affiliations
- Brigham and Women's Hospital (US)
- Georgetown University (US)
- Corresponding author
- Aroda, Vanita R.
- ORCID
- Aroda, Vanita R.
- Venue
- Diabetes Spectrum
- Publisher
- American Diabetes Association
- Published
- 2018-11-01
- Volume
- 31
- Issue
- 4
- Pages
- 336-342
- ISSN
- 1040-9165 (ISSN-L)
- 1944-7353
- PMC
- PMC6243218
- OpenAlex
- W2901945957
- Cited by
- 70
- References
- 32
- Citations by year
- 2026: 4 · 2025: 12 · 2024: 23 · 2023: 13 · 2022: 7 · 2021: 7 · 2020: 3 · 2019: 1
- FWCI
- 2.19
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Spectrum (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes prevention, prediabetes, Diabetes Prevention Program, lifestyle intervention, obesity, gestational diabetes mellitus, microvascular complications, atherosclerosis, coronary artery calcium, long-term follow-up
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.